Insight
‘Femtech addresses critical unmet needs in the women’s health space’

Dr Pamela Walker tells FemTech World everything we need to know about the femtech market.
Can you tell our readers a little bit about yourself?
I am a healthcare strategic growth specialist and award winning MedTech angel investor. I have been passionate about the healthcare space my whole life, and this drive pushed me to complete a PhD in Neuroscience, followed more recently by an Executive MBA (both from Oxford).
I have devoted my career to helping get treatments and medical devices to the patients that need them, and optimising the support patients, caregivers and healthcare professionals need to improve outcomes.
To make this impact, I work with Pharma and MedTech corporates as well as Private Equity and VC funds, advising on acquisitions and optimising commercialisations in the UK, US and worldwide. I am a Partner at Gate One, heading up the Life Sciences sector, Gate One Incubator and investment channel. I am also an avid investor with THENA Capital and Angel Academe, and board advisor to a number of our portfolio investments.
Why is it important to invest in femtech?
Femtech is an important sector, addressing critical unmet needs in the women’s health space. It leverages tech innovations that we have at our fingertips and applies them to critical gaps in healthcare for over 50 per cent of the world’s population.
In 2021, the gender healthcare gap gained visibility in the UK with the publication of the House of Lords Library report. This report highlights that the UK has the largest female health gap in the G20 and the 12th largest globally. This past summer, NHS England published its strategy on how the gap should be addressed.
Independent reports and inquiries have highlighted where this gap is most visible:
- Mental health, heart conditions, and pain treatment are some of the areas for which women are not offered the same level of care as men.
- Women’s health is under researched and is given a lower priority when it comes to health services: less is known about conditions that only affect women including common gynaecological conditions that can have severe impacts on health and wellbeing. For example, it takes seven to eight years for women to receive a diagnosis of endometriosis, with 40% of women needing 10 or more GP appointments before being referred to a specialist.
- Clinical research in women is dramatically lower than in men, and gender biases in clinical trials are contributing to worse health outcomes for women vs men.
This evidence has highlighted the need for greater focus on women’s health. The market must consider women as a sizeable consumer group. This is an underserved group that is increasingly educated, employed, and receiving attention from diversity and inclusion benchmarks at a global level.
Women represent an important consumer group to be marketed to and a discerning group that will prefer products relevant for them. Companies that consider them will win.
What do you think is missing in the femtech industry?
There are a number of novelty products and me-too solutions in this space, at the moment. Although there are products targeting key points in the female lifecycle, most, however, are still finding their feet. Some are missing a business model for longevity, others are very niche and will struggle to gain uptake, others have unclear value propositions. Overall, evidence of impact hasn’t quite yet pulled through, but there is a lot of excellent innovation kicking off.
From a product development standpoint, design and execution support is needed. There is a medium-term gap to address the gender healthcare gap imbalance through the drug and medical product development process. Innovations that optimise the development process with a gender balanced lens will be in demand.
What do you see in the future of femtech?
Meaningful, purposeful, and effective solutions. Holistic solutions that streamline and simplify tools/support/tech to the issues that matter most to women. These might include:
- Enablers to improve clinical research by gathering data and partnering with research centres. There is a need to accelerate understanding and research in women’s health whether it leads to better supporting female athletes or better understanding risk factors and treatment outcomes for women.
- Solutions that optimise pre-post natal and menopause (beyond education and community support) are key. Women have an important role to play in the global economy. At present, we aren’t achieving our full potential. Femtech is pivotal in this space to ensure that those who want, can fully participate and perform in the workforce, whatever stage of life they are at.
- Remote tech: Health systems are under pressure, solutions that empower women to engage with maintenance/ prevention of their health outside of hospitals (e.g. at home annual testing) are transformational.
- Innovations for earlier disease (eg cancer) detection: these can help to reduce the need for traumatic and expensive surgeries and treatments.
How can digital tools impact the femtech market?
FemTech by its very name is reliant heavily on tech innovation. Real impact will be:
- significant builds on current solutions that improve health outcomes and / or the female experience, OR
- carving out new solutions to unmet need spaces.
Leveraging nascent digital tools and optimising them for the female market (keeping this customer group at the heart of design, production and experience) will be critical to maximise impact.

Dr. Pamela Walker
Insight
Black women want more accessible breast cancer screening info, study finds

Black women in the UK want clearer, more accessible breast cancer screening information, research has found.
The study looked at why Black African and Black Caribbean women are less likely than white women to attend breast screening.
Researchers at the University of Surrey held focus groups and interviews with 47 Black African and Black Caribbean women aged 50 to 71.
Women in this age group are routinely invited for NHS breast screening.
The researchers said only 45 per cent of Black women attend screening, compared with 63 per cent of white women.
Anietie Aliu, lead author, postgraduate researcher at the University of Surrey and registered nurse, said: “Diagnosing breast cancer early can dramatically improve a person’s chance of survival.
“Breast cancer screening plays an important role in this by identifying the cancer and ensuring a person receives speedy treatment.
“Despite the importance of screening, Black women are less likely to attend appointments than white females.
“This puts them at risk of a potential cancer being diagnosed late and spreading to other areas of the body. We need to understand what is preventing Black women from attending these appointments and help identify ways to remove such barriers.”
The study found a need to increase awareness of breast cancer screening, especially among women less familiar with the service.
Some women, particularly those born outside the UK, knew little about breast screening before receiving their first invitation.
Others questioned why they needed screening when they had no symptoms.
The importance of trusted conversations was also identified.
Researchers found that some Black women expected their GPs to speak to them about breast screening, particularly before they reached screening age.
Although NHS breast screening is organised through national screening services, researchers said GPs often have established relationships with patients and may be well placed to offer brief advice on preventive care, including breast screening.
Participants called for stronger links between GP practices, breast screening services and Black community champions.
They said this could help women receive trusted information, ask questions and feel reassured.
Faith and religious beliefs also shaped decisions for some women.
Some Black African Christian women said illness, including cancer, was not permitted by God in their bodies, while others saw screening as a personal choice that did not conflict with Christian faith.
Muslim women highlighted the importance of being able to state their religion on medical appointment forms to help ensure they were seen by a female mammographer.
A mammographer is a healthcare professional trained to carry out breast screening scans.
Aliu added: “Breast screening can save lives, but our findings show that attendance is shaped by multiple factors, not just awareness, although awareness remains important.
“Women need relatable screening information, reassurance, flexible appointments and services that are accessible within their communities.
“Many felt that invitation letters were too formal, and that leaflets and media imagery did not reflect them, making it harder to relate to screening.”
Dr Afrodita Marcu, senior research fellow at the University of Surrey and member of the research team, said: “We need a more collaborative approach, where primary care, screening services and community voices work together to support women before, during and after the invitation.”
The researchers said future breast screening interventions should be designed with Black women, rather than for them.
They said user-friendly and culturally relevant resources, developed with communities, healthcare professionals and screening services, could improve understanding, reduce fear and make breast screening feel more accessible and reassuring.
Dr Robert Kerrison, associate professor of cancer care at the University of Surrey, said: “There is no question that breast screening can be lifesaving, but we need to make it easier for women to understand, access and feel reassured by the programme.
“This means improving communication, addressing practical barriers and making sure healthcare professionals and community partners are supported to provide clear and trusted information.”
The team has also explored healthcare professionals’ perspectives and worked with stakeholders to develop user-friendly materials with Black women.
Researchers said this co-designed approach could help ensure breast screening messages are culturally relevant, practical and shaped by the people they are intended to support.
News
“Women’s voices should be heard and pain should never be ignored,” says Wales’s first Women’s Health Minister

Women’s pain should not simply be endured, Wales’s first women’s health minister has said.
Delyth Jewell said she was determined to tackle the normalisation of pain in women’s healthcare and ensure women’s voices are listened to.
Speaking during a Women’s Health Summit at the Temple of Peace on Thursday, July 16, she said: “For too long, women’s health has been treated as an afterthought. No woman should be afraid to speak up about pain or things that don’t feel right.
“Women should be believed about their bodies, and I am determined to change the culture that has let too many women down.”
She added: “Women’s voices helped create the Women’s Health Plan. Now we’re making sure those voices continue to shape what comes next.”
The summit brought together clinicians, researchers and women with lived experience to tackle the normalisation of pain in healthcare and identify how women’s voices can better shape NHS services.
Lived experience means insight from people who have personally gone through a health issue or used healthcare services.
The event focused on pain linked to clinical procedures and long-term health conditions, drawing on research evidence, clinical expertise and women’s personal experiences.
Following the summit, minimum standards for service user engagement will be drafted to ensure women’s voices continue to influence the delivery and future priorities of the Women’s Health Plan.
Service user engagement means involving people who use health services in decisions about how care is designed, delivered and improved.
Work will also begin to refresh and strengthen the plan, including gathering feedback directly from women across Wales.
The NHS Wales Women’s Health Plan was developed after discovery work in 2022, when women across Wales shared their experiences of healthcare.
Many said they had not felt listened to, had symptoms dismissed or had lived with pain for years before receiving a diagnosis.
Insight
The Healthcare AI Playbook: What it actually takes to build trustworthy AI for care

Hosted by Amanda Ducach, CEO, and Morgan Rose, chief science officer, EmaEQ
Healthcare companies have spent the last two years hearing the same advice: get AI into your product. Few have been told what that actually takes.
Most default to the fastest option. Plug in a general-purpose model, wrap it in a chat window, and call the box checked. It looks like progress on a roadmap slide. It rarely holds up once a real patient is on the other end of it.
We’ve spent years building AI specifically for healthcare, and the lesson that keeps repeating itself is simple: accuracy is not the same thing as trust, and trust isn’t something you bolt on after launch. It has to be part of how the system is built from the first line of code, not a feature added once regulators or users start asking questions.
That distinction is the whole reason clinical accuracy gets treated as a checkbox instead of a discipline. A model can sound confident and still be wrong in ways that matter enormously in a health context.
Knowing the difference, and building for it deliberately, is what separates AI that’s genuinely safe for care from AI that’s simply fast to ship.
On July 20th, we’re hosting a live conversation about exactly this: what companies should be paying attention to before they choose an AI to build with, what clinical accuracy really requires, and the pillars we hold every AI system to before it gets anywhere near a patient’s care.
The Healthcare AI Playbook Webinar: July 20th, 1:30-2pm EST, live on LinkedIn.
Register here: https://www.linkedin.com/events/7482643171823509504?viewAsMember=true
If your team is building anywhere near healthcare, or evaluating what’s already in your product, this is the conversation we think the industry needs right now.
Diagnosis2 weeks agoTwo “gamechanger” tests set to speed up endometriosis diagnosis on the NHS
Fertility2 weeks agoWomen with PMOS should have annual NHS checks, new guidance says
News4 days agoNew menopause drug approved for use by NHS in Scotland
Cancer2 weeks agoThousands of women could avoid painful cancer exam with new AI blood test
Entrepreneur1 week agoApplications open for the third W Accelerate with Merck KGaA and M Ventures
Fertility2 weeks agoOlder women face lower chance of fertility treatment working, even with donor eggs, study finds
News2 weeks agoWe built Ema like a nurse: Here’s why that matters
News2 weeks agoExperts call for regulation of toxic period product chemicals













4 Comments